Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Thrombotic Thrombocytopenic Purpura
100%
Disease
31%
Antiphospholipid Syndrome
26%
Thrombosis
23%
Sickle-Cell Disease
21%
Atypical Hemolytic Uremic Syndrome
20%
Thrombocytopenia
19%
Bleeding
18%
Apoplexy
18%
Cardiovascular Disease
17%
Platelet
15%
Anticoagulation
14%
Antiphospholipid Antibody
14%
Von Willebrand Factor Cleaving Proteinase
13%
Venous Thromboembolism
12%
Complement Activation
12%
Idiopathic Thrombocytopenic Purpura
11%
Microangiopathy
11%
Eculizumab
11%
Bloodless Surgery
11%
Systematic Review
11%
Caplacizumab
11%
Catastrophic Antiphospholipid Syndrome
9%
Quality of Life
9%
Infarction
8%
Prevalence
8%
Survivorship in Cancer Care
8%
Health Care Cost
8%
Plasma Exchange
7%
Myeloproliferative Neoplasm
7%
Heparin-Induced Thrombocytopenia
7%
Meta-Analysis
7%
Early Diagnosis
7%
Effective Treatment
7%
Pathophysiology
7%
Von Willebrand Factor
7%
Targeted Therapy
7%
Cerebral Hemorrhage
7%
Clinician
6%
Complement Component C5b
6%
Retrospective Cohort Study
6%
Coagulopathy
6%
Hazard Ratio
6%
Brain Ischemia
6%
Complement Inhibition
6%
Pediatrics
6%
Thromboplastin
5%
Pediatrics Patient
5%
Prostate Cancer
5%
Heparin
5%
Keyphrases
Immune Thrombocytopenic Purpura
52%
Thrombotic Thrombocytopenic Purpura
36%
Survivors
29%
Antiphospholipid Syndrome
26%
Thrombocytopenia
24%
Thrombosis
18%
Atypical Hemolytic Uremic Syndrome (aHUS)
17%
Thrombotic Microangiopathy
15%
Sickle Cell Disease
13%
Confidence Interval
13%
ADAMTS13
11%
Antiphospholipid Antibodies
11%
Remission
10%
Clinical Outcomes
10%
Eculizumab
10%
Rituximab
10%
United States
10%
Anticoagulation
10%
Risk Factors
10%
Alternative Complement Pathway
9%
Odds Ratio
9%
Cardiovascular Disease
9%
Caplacizumab
9%
Venous Thromboembolism
9%
Bleeding
8%
Catastrophic Antiphospholipid Syndrome
8%
Clinical Remission
7%
Bloodless Surgery
7%
Myeloproliferative Neoplasms
7%
Survivorship
7%
Hereditary Hemorrhagic Telangiectasia
7%
Posttraumatic Stress Disorder
7%
Thrombocytopenia in Pregnancy
7%
Sickle Cell Anemia
7%
Older Adults
7%
Subnational Analysis
7%
Silent Cerebral Infarction
7%
Immune Response
7%
Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
7%
Cognitive Impairment
6%
Stent Thrombosis
6%
Hazard Ratio
6%
Pregnancy Outcome
6%
Major Adverse Cardiovascular Events
6%
Low Platelet Count
6%
Black Men
6%
Aspirin
5%
Preeclampsia
5%
Elevated Liver Enzymes
5%
Incidental
5%
Pharmacology, Toxicology and Pharmaceutical Science
Thrombotic Thrombocytopenic Purpura
76%
Von Willebrand Factor Cleaving Proteinase
16%
Antiphospholipid Syndrome
14%
Thrombosis
14%
Remission
12%
Cardiovascular Disease
12%
Idiopathic Thrombocytopenic Purpura
11%
Antiphospholipid Antibody
10%
Prevalence
9%
Bleeding
9%
Von Willebrand Factor
8%
Rituximab
7%
Caplacizumab
7%
Disease
7%
Posttraumatic Stress Disorder
7%
Thrombocytopenia
7%
Cerebrovascular Accident
7%
Brain Hemorrhage
7%
Pathophysiology
6%
Brain Ischemia
5%
Venous Thromboembolism
5%
Syndrome
5%
Prostate Cancer
5%
Cardiovascular Risk
5%